title: Small agarose microcapsules with cell-enclosing hollow core for cell therapy: transplantation of Ifosfamide-activating cells to the mice with preestablished subcutaneous tumor.
abstract: Cell transplantation after enclosing in microcapsules has been studied as an alternative approach for treatment of wide variety of diseases. In the present study, we examined the feasibility of using agarose microcapsules, having a cell-enclosing hollow core of 100-150 microm in diameter and agarose gel membrane of about 20 microm in thickness, as a device for the methodology. We enclosed cells that had been genetically engineered to express cytochrome P450 2B1, an enzyme that activates the anticancer prodrug ifosfamide. The enclosed cells were shown to express the enzymatic function in the microcapsules in that they suppressed the growth of tumor cells in medium containing ifosfamide. In addition, a more significant regression of preformed tumors was observed in the nude mice implanted with the cell-enclosing microcapsules compared with those implanted with empty capsules after administration of ifosfamide. Preformed tumors shrank by less than 40% in volume in 6 of the 10 recipients implanted with cell-enclosing microcapsules. In contrast, only 1 in 10 of the preformed tumors in the recipient implanted with empty microcapsules shrank by this amount. These results suggest that agarose microcapsules containing cytochrome P450 2B1 enzyme-expressing cells are feasible devices for improving the chemotherapy of tumors. Thus, agarose microcapsule having hollow cores are generally a good candidate as vehicles for cell-encapsulation approaches to cell therapy.
authors.affiliation: Department of Chemical Engineering, Faculty of Engineering, Kyushu University, Nishiku, Fukuoka-city, Fukuoka, Japan. sakai@chem-eng.kyushu-u.ac.jp
authors.forename: Shinji
authors.initials: S
authors.lastname: Sakai
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hashimoto
authors.forename: Shinji
authors.initials: S
authors.lastname: Tanaka
authors.forename: Brian
authors.initials: B
authors.lastname: Salmons
authors.forename: Koei
authors.initials: K
authors.lastname: Kawakami
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D002214:Capsules / Q000737:chemistry / Q000627:therapeutic use*; D017690:Cell Transplantation / Q000379:methods*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D019362:Cytochrome P-450 CYP2B1 / Q000235:genetics / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods; D007069:Ifosfamide / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D012685:Sepharose / Q000737:chemistry / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002214:Capsules; D012685:Sepharose; D019362:Cytochrome P-450 CYP2B1; D007069:Ifosfamide